Rail Vision completes proof of concept test in India

Rail Vision Ltd. (NASDAQ: RVSN) completed a proof of concept demonstration of its MainLine system with a major rail operator in India, the company announced March 16. The two-month evaluation was conducted in collaboration with Sujan Industries, a supplier to the Indian rail industry.

The test assessed the MainLine system's real-time object detection and classification performance, operational stability, and effectiveness under varying environmental conditions. Rail Vision received an official report from the customer indicating positive feedback regarding the system's performance and suitability for further evaluation and potential controlled deployment.

The MainLine system uses sensing and analytics to detect and classify potential hazards and alert train operators at distances up to 2,000 meters ahead of the train.

"Successfully completing this POC and demonstrating our MainLine system in real-world operating conditions is an important achievement for Rail Vision," said David BenDavid, CEO of Rail Vision. "Receiving positive feedback from the customer following the evaluation reinforces our confidence in the value our technology can bring to railway operators in the region."

"We are pleased with the evaluation results and the opportunities they highlight for Indian rail operators," said Brijesh Sujan, CEO of Sujan Industries. "We believe the POC underscores the potential of Rail Vision's technology to enhance operational safety and efficiency."

Rail Vision and Sujan Industries plan to continue working together to pursue additional opportunities in India. The company stated it is advancing several potential opportunities in the Indian market.

Rail Vision develops AI-integrated sensing systems for railway safety and is based in Ra'anana, Israel.

You May Also Be Interested In

• Gulfport Energy and Mobility Global to join S&P SmallCap 600
• Magnolia Said In Lead To Acquire Wildfire For Over $4 Billion - Bloomberg
• FDA approves AbbVie's Skyrizi for children with psoriatic disease